Summary of the characteristic of the included studies.
Reference (country) | N (F/M) Age mean±SD or median (range) |
Detection of HP infection (follow up period) |
Duration of ITP (type of ITP relapse) |
Platelet count at enrollment | Platelet after treatment | Response in all infected patients | Eradicated patients (non-eradicated patients) |
---|---|---|---|---|---|---|---|
Iran [18] | 29.2±7.0 (18–46) | 79 patients were infected & only 71 completed eradication | 61 mo (6–210 mo) | 58.32±17.74×109/L (range, 31–96×109/L) | Eradicated patients137.77×109/L | Response in 30 eradicated patients | 62 |
29.2±7.0 (18–46) | Chronic | 9 | |||||
1 yr | NR | CR: 30 | |||||
Iran [19] | 30 (67/33) | 5 patients were infected | NR | 20×109/L (10–30×109/L) | 81×109/L (69–89×109/L) | Response in 5 eradicated patients | 5 |
12 (9–16) | Chronic | PR: 4 | 0 | ||||
1 yr | 1 out of 5 eradicated patients (20%) | CR: 0 | |||||
PR+CR: 4 patients | |||||||
Iran [20] | 52 (50/50 in 26 patients) | NR | 57.9×109/L (22–96×109/L) | 104×109/L (26–196×109/L) | Response in 26 eradicated patients | 26 | |
NR | CR: 15 | 3 | |||||
38 (17–71) | NR | PR: 0 | |||||
6 mo | PR+CR: 15 | ||||||
Iran [21] | 92 (53/47) | Only 47 patients remained after excluding other patients | 2.2 mo (1–4.5 mo) | 34.6×109/L (21–48×109/L) | 52.8×109/L (23–86×109/L) | Response in 41 eradicated patients | 41 |
41 (19–71) | CR: 0 | 6 | |||||
Chronic | ( |
PR: 3 | |||||
6 mo | NR | PR+CR: 3 | |||||
Pakistan [22] | 197 (54.5/45.5 in 22 patient) | 22 patients were infected | NR | 53.36±24.5×109/L | 80.86±51.0×109/L | Response in 22 infected patients | 7 |
NR | CR: 7 | 15 | |||||
43.18±12.5 yr | NR | NR | PR: 10 | ||||
PR+CR: 17 | |||||||
Pakistan [23] | 85 (62.3/37.6) | 34 patients were infected | NR | 48.56±21.7×109/L | 94.2±26.8×109/L | Response in 34 eradicated patients | 34 |
Infected patients: 43.89±7.06 | Chronic | CR: 19 | 0 | ||||
Uninfected patients: 44.75±7.91 | NR | NR | PR: 10 | ||||
PR+CR: 29 | |||||||
Turkey [24] | 34 (35.3/64.7) | 20 patients were infected | NR | 39.7±19.2×109/L | 164.2±63.2×109/L | Response in 18 eradicated patients | 18 |
52.5 yr (range, 16–93) | Chronic | CR: 5/18 | 2 | ||||
13 mo | NR | PR: 3/18 | |||||
PR+CR: 8 |
Abbreviations: CR, complete response; ITP, immune thrombocytopenia; NR, not reported; PR, partial response.